Background: Proton-pump inhibitors (PPIs) are commonly used in clinical practice for gastric acid suppression. However, these agents have also been associated with certain negative clinical outcomes. We evaluated the real-world effects of incident PPI use on clinical outcomes in patients with Staphylococcus aureus bacteremia. Methods: This retrospective cohort study included patients admitted to Veterans Affairs hospitals with positive S. aureus blood cultures collected between 2002 and 2013 that received appropriate antibiotics within 48 hours of culture collection. Clinical outcomes among three PPI exposure groups, each compared to nonusers, were assessed with propensity-scorematched Cox proportional-hazard regression models: pretreated PPI users initiating therapy in the 30 days prior to culture and either (a) continuing PPI therapy after culture, or (b) not continuing after culture, and (c) de novo users initiating at culture. Results: Clinical outcomes, including inpatient mortality, intensive care discharge, 30day mortality, 30-day readmission, and 30-day Clostridium difficile infection (CDI) were similar among PPI users and nonusers. Though length of stay was longer in pretreated, continuing PPI users [time-to-discharge hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.65-0.93], 14-day mortality was significantly lower than in nonusers (HR 0.66, 95% CI 0.50-0.87).
Introduction
Proton-pump inhibitors (PPIs) are commonly used in clinical practice for gastric-acid suppression, particularly for the prevention of stress ulcers in critically ill patients. However, an increased risk of some negative clinical outcomes has been reported, including kidney disease, hypomagnesemia, bone fractures, pneumonia, and Clostridium difficile infections (CDIs). 1, 2 A recent study raised alarm by suggesting that initiating PPIs during hospital admission could increase the risk of inpatient mortality by about 90%. 3 While older data have suggested that acid suppression allows for increased intestinal bacteria, some analyses found this overgrowth occurred less with histamine antagonists, conceivably related to less potent gastric-acid suppression from histamine antagonists when compared with PPIs. 4 Moreover, PPIs have been associated with decreased leukocyte antimicrobial activity in vitro, as well as attenuated innate immune responses in vivo that may be beneficial in clearance of bacterial infection. 5 We thought it would be important to examine if these reported immunomodulatory effects described for PPIs translated into any clinical outcome differences in patients with invasive infection. Among the most common of invasive bacterial infection in humans, Staphylococcus aureus affects broad patient populations exhibiting high diversity in baseline host innate immune status. This study sought to evaluate the real-world effects of incident PPI use on clinical outcomes in patients with S. aureus bacteremia.
Methods

Data source
We utilized national Veterans Affairs (VA) databases, which contain health and administrative data captured from electronic medical records. The databases used included diagnoses and procedures from outpatient and inpatient care, laboratory and microbiology results, vital signs and vital status, and pharmacy data, including inpatient and outpatient administration and dispensing, and medications prescribed by non-VA providers or purchased by patients at non-VA pharmacies.
Study population
This retrospective cohort study included adult patients (age ⩾ 18 years) admitted to VA hospitals with positive blood cultures for S. aureus between 1 January 2002 and 1 December 2013. Initial antibiotic regimens within 48 hours of culture collection were reviewed and only those with appropriate regimens were selected for inclusion: intravenous β-lactam therapy (ampicillin-sulbactam, nafcillin, oxacillin, piperacillin-tazobactam, cefazolin, cefotetan, cefoxitin, ceftazidime, ceftriaxone, ceftaroline, ertapenem, doripenem, imipenem-cilastatin, or meropenem) or vancomycin for methicillin-susceptible S. aureus (MSSA) and vancomycin or ceftaroline for methicillin-resistant S. aureus (MRSA). If patients were discharged within 1 day of culture or died in that same timeframe, they were excluded. Once these criteria were applied, the first admission was selected for analysis.
This study was approved by the Institutional Review Board and Research and Development Committee of the Providence Veterans Affairs Medical Center.
As this study utilized existing health data, a waiver of informed consent was granted by the Institutional Review Board of the Providence Veterans Affairs Medical Center.
PPI use
Incident PPI use was defined as initiation of a PPI within the 30 days prior to culture or at culture, without PPI use in the previous year. Those initiating prior to culture were further categorized as continuing after culture and not continuing after culture, to assess whether lasting effects were observed after discontinuation. Nonusers were those with no record of PPI use in the year prior to culture or during the entire admission and served as the comparison group for all three PPI user groups (pretreated with continuation, pretreated without continuation, and de novo at culture).
Outcomes
The primary outcome was mortality as assessed within 30 days of the culture collection date and the secondary outcomes included 14-day mortality, inpatient mortality, hospital discharge, intensive care unit (ICU) discharge, 30-day readmission, and 30-day CDI (International Classification of Diseases, 9th edition, 008.45). We calculated time for each endpoint from the culture collection date to the event date, and censoring was used in the assessments of discharge, readmission, and CDI for patients who died.
Statistical analysis
We developed three separate propensity-score models for each PPI exposure group that controlled for initial antibiotic treatment, treating facility, treating specialty, infection source, previous healthcare exposures, demographics, current comorbidities, medical history, and other clinical characteristics, such as MSSA/ MRSA (Appendix 1 in the Supplementary Material). We confirmed goodness of fit and absence of multicollinearity in the propensity-score models. Nonusers were then matched to users on their propensity score using nearest neighbor matching within 0.005 caliper. Lastly, Cox proportional hazard regression models were used to quantify the hazard ratio (HR) and 95% confidence interval (CI) for all outcomes. Analyses were performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Our study included 653 pretreated PPI users without continuation, 642 pretreated PPI users with continuation, 900 de novo PPI users, and 11,840 nonusers, all with S. aureus bacteremia ( Figure 1 ). groups prior to implementation of propensityscore matching. PPI users differed considerably from nonusers, in terms of demographic characteristics, source of infection, comorbidity burden, and medical history. Due to these significant differences, these variables were included in the propensity-score models. Each model demonstrated goodness of fit, allowing strong discrimination between the groups, with high C statistics of 0.82-0.90, and due to the small caliper used for identifying matches, complete overlap in propensity-score distributions between PPI users and nonusers was obtained.
In propensity-matched analyses of the aforementioned clinical outcomes, there were few differences observed between PPI users and nonusers ( Median time to antibiotic treatment initiation from culture collection (days) 0 (0-1) 0 (0-1) 0 (0-1) 0 (0-1)
Median length of antibiotic therapy (days) with continuation, despite a lower discharge rate (HR 0.74, 0.60-0.90), and a lower discharge rate was also observed for de novo PPI users (HR 0.75, 95% CI 0.64-0.87; data not presented in tables).
Discussion
PPIs have been shown in various studies to inhibit neutrophil functions that are critical in bacterial clearance, including production of reactive oxidative species, chemotaxis, and phagolysozome acidification. 6, 7 In addition, certain PPIs are reported to reduce expression of integrins CD11b and CD18 on the neutrophil surface and expression of adhesion molecules ICAM-1 and VCAM-1 on endothelial cells, potentially compromising transcytosis of the immune cells to tissue foci of infection. 8 Consistent with such laboratory data is Seeking to determine whether PPIs influence clinical outcomes in patients with S. aureus bacteremia, we found similar outcomes between PPI users with varying exposure patterns as compared with nonusers, in agreement with a recent metaanalysis of 19 randomized trials conducted among critically ill patients. 9 As the included randomized trials evaluated prophylactic PPI use, these studies most likely reflect a de novo exposure pattern, however the number of studies excluding patients with preadmission PPI use was not reported. Pneumonia, mortality, and ICU length of stay were similar among those randomzied to PPIs versus histamine-2-receptor antagonists (H2RAs), with a relative risk of 1.12 (95% CI 0.86-1.46) and 1.05 (95% CI 0.87-1.27) for pneumonia and mortality, respectively, and a mean difference in ICU length of stay of −0.38 days (95% CI −1.49 to 0.74). None of the included 19 studies reported CDIs.
While multiple meta-analyses have found an association between PPI use and CDIs, heterogeneity among studies evaluated has been consistently high (I 2 > 85%) reflecting variability in the associated risk among studies, and significant limitations of existing studies have been noted. 10, 11 A recent study evaluating the risk of CDI among intensive care unit patients suggests some patient populations may not have the same associated risk, consistent with our results. 12 In this large multicenter study among 18,134 patients, PPI use did not lead to a significant increase in CDI [adjusted hazard ratio (aHR) 1.56; 95% CI 0.72-3.35] among patients not receiving antibiotics and was protective in those receiving antibiotics (aHR 0.64; 95% CI 0.48-0.83). Further studies should seek to determine in which patient populations PPIs may be safely used without conferring increased CDI risk.
Several limitations to our study should be noted. First, over-the-counter use of PPIs may not have been reported during clinical visits and hospitalizations. Second, we utilized diagnosis codes to operationally define certain conditions, such as CDI, which may result in misclassification. For example, presence of diagnosis codes may not always reflect active problems and may be used to reflect history of the condition, or even colonization in the case of C. difficile. Third, residual confounding may be present due to unmeasured confounders, despite our efforts to control for many confounders using propensity-score methods. Fourth, our study was conducted among patients receiving care at VA hospitals, and included mostly older males.
Conclusion
Rates of negative clinical outcomes were similar among PPI users and nonusers in our large, national, real-world cohort study. As this is one observational study from a single-study population, our results should be substantiated in other study populations. If rates of negative clinical outcomes, such as mortality and CDI, are found to be similar between PPI users and nonusers with serious infections then the clinical benefits of PPI use under appropriate indications may outweigh the potential risk of certain other adverse events that have been attributed to PPI use.
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